| CPC C12N 15/113 (2013.01) [A61K 35/76 (2013.01); A61K 48/005 (2013.01); A61P 35/04 (2018.01); C12N 2310/11 (2013.01); C12N 2310/3233 (2013.01); C12N 2320/33 (2013.01)] | 5 Claims |

|
1. A method for treating a disease in a patient, characterized by upregulated expression of periostin splice variant containing exon 17 or exon 21 after the onset of the disease, the method comprising:
administering to the patient, an effective amount of a nucleic acid that induces skipping of exon 17 of periostin gene or an effective amount of a nucleic acid that induces skipping of exon 21 of periostin gene, wherein the disease is selected from the group consisting of heart failure, renal failure, breast cancer, pancreatic cancer, malignant melanoma, bronchial asthma, diabetic retinopathy, knee osteoarthritis, idiopathic interstitial pneumonia, and age-related macular degeneration;
wherein the nucleic acid is an antisense nucleic acid;
wherein the antisense nucleic acid that induces skipping of exon 17 is one or more antisense nucleic acids of 14 to 50 bases in length, which target the region of positions 24143 to 24323; and
wherein the antisense nucleic acid that induces skipping of exon 21 is one or more antisense nucleic acids of 14 to 50 bases, which target the region of positions 29412 to 29595, of the nucleotide sequence represented by SEQ ID NO: 1.
|